This Coronavirus Doesn't Change Quickly, And That's Good News For Vaccine Makers
Publication date: Available online 30 June 2020Source: Advances in Virus ResearchAuthor(s): Zhiqian Ma, Zhiwei Li, Linfang Dong, Ting Yang, Shuqi Xiao
An experimental coronavirus vaccine developed by Inovio Pharmaceuticals Inc showed promise and was found to be safe in an early-stage human trial, the company said on Tuesday.Reuters Health Information
[Thomson Reuters Foundation] The founder of the microcredit movement Muhammad Yunus fears poor countries will be left behind
Stocks moved higher to start the third quarter.
Here are answers to some of your questions about COVID-19 as the U.S. sees a spike in new cases.
[New Zimbabwe] A newly established pressure group, the International Coalition Against Coronavirus (ICAC) is mobilising local citizens to reject the Covid-19 vaccine trials as they cause "unnecessary" deaths.
(Innovation Center of NanoMedicine) The Innovation Center of NanoMedicine (iCONM) and the Tokyo Metropolitan Institute of Medical Science (TMIMS) started joint research with the aim of establishing a rapid vaccine development technology in preparation for the re-epidemic of covid-19 and the next coming pandemic of further new coronaviruses. An efficient procedure for the production of mRNA vaccine incorporated with immunostimulatory adjuvant functionality will be optimized using iCONM's smart nanomachine technologies and TMIMS's expertise for the discovery of recombinant vaccines.
The Bill&Melinda Gates Foundation is contributing hundreds of millions of dollars toward Covid-19 vaccine trials. Bill Gates sits down with CNN Chief Medical Correspondent Dr. Sanjay Gupta and CNN's Anderson Cooper to discuss the prospect of developing a vaccine.
The Chinese government has approved the use of an experimental Covid-19 vaccine for the country's military -- the latest step in a global race to stop the deadly disease caused by the novel coronavirus.
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus (SARS-CoV)-2 has resulted in the death of more than 328,000 persons worldwide in the first 5 months of 2020. Herculean efforts to rapidly design and produce vaccines and other antiviral interventions are ongoing. However, newly evolving viral mutations, the prospect of only temporary immunity, and a long path to regulatory approval pose significant challenges and call for a common, readily available, and inexpensive treatment. Strategic drug repurposing combined with rapid testing of established molecular targets could ...